Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
What are the Ovaries?
The ovaries are a pair of organs in the female reproductive system that produce eggs and female hormones.
Due to a lack of effective screening and diagnostic tools, more than three-fourths of ovarian cancer cases are not found until the cancer is in an advanced stage.
A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).
Women who breastfed were less likely to develop heart disease or a stroke, or die from cardiovascular disease than women who did not breastfeed, according to a meta-analysis published today in a pregnancy spotlight issue of the Journal of the American Heart Association (JAHA), an open access, peer-reviewed journal of the American Heart Association.
Stem cell scientists have revealed the origins of a common ovarian cancer by modeling fallopian tube tissues, allowing them to characterize how a genetic mutation puts women at high risk for this cancer.
A team of scientists led by the University of Michigan Health Rogel Cancer Center has found that a class of U.S. Food and Drug Administration-approved drugs can effectively stop a highly aggressive type of uterine cancer in its tracks, paving a quick path toward new treatment strategies for a deadly cancer with limited therapeutic options.
Use of certain personal care products during pregnancy may impact maternal hormone levels, according to a new Rutgers study.
A study of over 200,500 women who had a hysterectomy for non-cancerous reasons found an increased risk of death in women under 50 years of age when the ovaries and fallopian tubes were also removed during the surgery. The same association was not found in women over 50.
Examination of Japanese cases of gynecological cancer offers a better understanding of the profile of a rare ovarian tumor and could change treatment guidelines.
Immunotherapies have shown striking clinical benefit in the treatment of many cancers, especially when used in combination with chemotherapy.
The U.S. Food and Drug Administration (FDA) today approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light, allowing surgeons to more easily find and more precisely remove the cancer.
A review highlights the prospects and challenges of RDW as a predictive biomarker for viral infections, with a special focus on COVID-19 and hepatitis.
Around 870 cases of ovarian cancer are reported in Belgium every year. Most of these patients are treated with surgical interventions and/or chemotherapy.
Immune checkpoint inhibitors are a type of cancer treatment that help the immune system's T cells recognize and attack tumors. But these immunotherapy drugs aren't effective against all cancers.
A Ludwig Cancer Research study has uncovered a cellular interaction that is essential to the ability of the immune system's cytotoxic T lymphocytes to destroy ovarian tumors and shown that its engagement could help determine the efficacy of checkpoint blockade immunotherapy in a variety of cancers.
Today, machine learning, artificial intelligence, and algorithmic advancements made by research scientists and engineers are driving more targeted medical therapies through the power of prediction.
TG2, an enzyme known to help cancers spread more quickly, also plays a role in regulating T-cells, according to a Northwestern Medicine study published in the Journal for Immunotherapy of Cancer.
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered that loss of ARID1A function enhances a cellular stress response pathway that promotes survival of cancer cells, which become sensitive to pharmacological inhibition of this pathway. These findings were published online in Cancer Research, a journal of the American Association for Cancer Research, and point to a new therapeutic opportunity for this type of ovarian cancer for which new solutions are urgently needed.
Treatment with estrogen in menopause is both good and bad for women's health. The picture is complex and the scientific evidence sometimes scanty or only moderately solid, a study shows. University of Gothenburg researchers took part.
One of the most impactful advancements during the past decade in treating ovarian cancer is the use of PARP inhibitors (short for poly adenosine diphosphate-ribose polymerase). PARP inhibitors are a type of cancer drug that blocks the PARP enzyme from helping to repair DNA damage in cancer cells.